Zoetis has been granted a patent for a method to induce a protective immune response in porcine animals against PRRS virus. The method involves administering a vaccine with a genetically-modified virus before weaning, ensuring safety and efficacy even in animals less than two weeks old. The vaccine reduces mortality compared to unvaccinated animals. GlobalData’s report on Zoetis gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Zoetis, Personalized cancer vaccines was a key innovation area identified from patents. Zoetis's grant share as of February 2024 was 54%. Grant share is based on the ratio of number of grants to total number of patents.
Vaccine for protecting porcine animals from prrs virus
A recently granted patent (Publication Number: US11911454B2) discloses a method for inducing a protective immune response in porcine animals against Porcine Reproductive and Respiratory Syndrome (PRRS) virus infection. The method involves administering a vaccine containing a modified live PRRS virus and a carrier suitable for veterinary use to the animals before weaning, even as early as two weeks of age. The modified live PRRS virus is prepared by attenuating a virulent PRRS virus in mammalian cells expressing porcine CD163 receptor protein, resulting in a safe and immunoprotective vaccine that reduces mortality in infected animals compared to unvaccinated ones.
Furthermore, the patent claims include variations in the vaccine composition, such as the addition of immunoprotection-inducing antigens from Mycoplasma hyopneumoniae and Porcine Circovirus Type 2, as well as the use of modified live European, North American, or Chinese PRRS viruses. The protective immune response induced by the vaccine can last up to 6 months, with the option of administering the vaccine to animals as young as one day old. Another aspect of the patent involves a method for inducing protective immunity using a modified live PRRS virus, an infectious RNA molecule encoding the virus, or a viral vector carrying the virus, all administered before weaning to elicit a protective immune response against wild-type PRRS virus infection, resulting in reduced mortality in infected animals.
To know more about GlobalData’s detailed insights on Zoetis, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
